- Home
- UHS vs QGEN Comparison
UHS vs QGEN Comparison
Compare UHS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHS | QGEN |
|---|---|---|
| Founded | 1978 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.0B |
| IPO Year | 1994 | 1998 |
Fundamental Metrics
Financial Performance| Metric | UHS | QGEN |
|---|---|---|
| Price | $182.76 | $46.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 16 |
| Target Price | ★ $196.12 | $48.13 |
| AVG Volume (30 Days) | 638.0K | ★ 1.9M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | 0.43% | ★ 5.98% |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 11.63 | N/A |
| Revenue | ★ $17,364,829,000.00 | N/A |
| Revenue This Year | $7.12 | $2.16 |
| Revenue Next Year | $4.80 | $5.06 |
| P/E Ratio | ★ $16.13 | $24.01 |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $140.08 | $32.53 |
| 52 Week High | $246.33 | $57.82 |
Technical Indicators
Market Signals| Indicator | UHS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 59.75 |
| Support Level | $182.25 | $46.07 |
| Resistance Level | $185.22 | $47.28 |
| Average True Range (ATR) | 3.74 | 1.05 |
| MACD | 0.73 | 0.11 |
| Stochastic Oscillator | 56.29 | 78.65 |
Price Performance
Historical ComparisonAbout UHS Universal Health Services Inc.
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).